Urine proteome of autosomal dominant polycystic kidney disease patients

被引:43
作者
Magda Bakun
Mariusz Niemczyk
Dominik Domanski
Radek Jazwiec
Anna Perzanowska
Stanislaw Niemczyk
Michal Kistowski
Agnieszka Fabijanska
Agnieszka Borowiec
Leszek Paczek
Michal Dadlez
机构
[1] Mass Spectrometry Laboratory, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106, Warsaw
[2] Department of Immunology,Transplant Medicine and Internal Medicine, Medical University of Warsaw, Warsaw
[3] Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine, Warsaw
[4] Department of Biology, Warsaw University, Warsaw
关键词
ADPKD; Differential proteomics; ITRAQ; Mass spectrometry; MRM; Urine proteome;
D O I
10.1186/1559-0275-9-13
中图分类号
学科分类号
摘要
Background: Autosomal dominant polycystic kidney disease (ADPKD) is responsible for 10% of cases of the end stage renal disease. Early diagnosis, especially of potential fast progressors would be of benefit for efficient planning of therapy. Urine excreted proteome has become a promising field of the search for marker patterns of renal diseases including ADPKD. Up to now however, only the low molecular weight fraction of ADPKD proteomic fingerprint was studied. The aim of our study was to characterize the higher molecular weight fraction of urinary proteome of ADPKD population in comparison to healthy controls as a part of a general effort aiming at exhaustive characterization of human urine proteome in health and disease, preceding establishment of clinically useful disease marker panel. Results: We have analyzed the protein composition of urine retentate (>10 kDa cutoff) from 30 ADPKD patients and an appropriate healthy control group by means of a gel-free relative quantitation of a set of more than 1400 proteins. We have identified an ADPKD-characteristic footprint of 155 proteins significantly up- or downrepresented in the urine of ADPKD patients. We have found changes in proteins of complement system, apolipoproteins, serpins, several growth factors in addition to known collagens and extracellular matrix components. For a subset of these proteins we have confirmed the results using an alternative analytical technique. Conclusions: Obtained results provide basis for further characterization of pathomechanism underlying the observed differences and establishing the proteomic prognostic marker panel. © 2012 Bakun et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 22 条
[1]  
Chang M.Y., Ong A.C.M., Autosomal dominant polycystic kidney disease: Recent advances in pathogenesis and treatment, Nephron Physiol, 108, pp. 1-7, (2008)
[2]  
Torres V.E., Meijer E., Bae K.T., Et al., Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 study, Am J Kidney Dis, 57, 5, pp. 692-699, (2011)
[3]  
Walz G., Budde K., Mannaa M., Et al., Everolimus in patients with autosomal dominant polycystic kidney disease, N Engl J Med, 363, 9, pp. 830-840, (2010)
[4]  
Serra A.L., Poster D., Kistler A.D., Et al., Sirolimus and kidney growth in autosomal dominant polycystic kidney disease, N Engl J Med, 363, 9, pp. 820-829, (2010)
[5]  
Hogan M.C., Masyuk T.V., Page L.J., Et al., Randomized clinical trial of longacting somatostatin for autosomal dominant polycystic kidney and liver disease, J Am Soc Nephrol, 21, 6, pp. 1052-1061, (2010)
[6]  
Julian B.A., Wittke S., Haubitz M., Et al., Urinary biomarkers of IgA nephropathy and other IgA-associated renal diseases, World J Urol, 25, (2007)
[7]  
Mason S.B., Lai X., Bacallao R.L., Et al., The biomarker enriched proteome of autosomal dominant polycystic kidney disease cyst fluid, Proteomics Clin Appl, 3, pp. 1247-1250, (2009)
[8]  
Kistler A.D., Mischak H., Poster D., Et al., Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease, Kidney Int, 76, pp. 89-96, (2009)
[9]  
Nagaraj N., Mann M., Quantitative analysis of the intra- And inter- individual variability of the normal urinary proteome, J Proteome Res, 10, 2, pp. 637-645, (2011)
[10]  
Marimuthu A., O'Meally R.N., Chaerkady R., Et al., A comprehensive map of the human urinary proteome, J Proteome Res, 10, 6, pp. 2734-2743, (2011)